These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33983574)

  • 1. Ras Signaling in Breast Cancer.
    Moon A
    Adv Exp Med Biol; 2021; 1187():81-101. PubMed ID: 33983574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
    Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
    Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.
    Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
    Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway.
    Clark JW; Santos-Moore A; Stevenson LE; Frackelton AR
    Int J Cancer; 1996 Jan; 65(2):186-91. PubMed ID: 8567115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant function of the Ras signal transduction pathway in human breast cancer.
    Clark GJ; Der CJ
    Breast Cancer Res Treat; 1995 Jul; 35(1):133-44. PubMed ID: 7612899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization.
    Lo HW; Hsu SC; Hung MC
    Breast Cancer Res Treat; 2006 Feb; 95(3):211-8. PubMed ID: 16261406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.
    Young A; Lou D; McCormick F
    Cancer Discov; 2013 Jan; 3(1):112-23. PubMed ID: 23103856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
    Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
    Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
    Choi C; Kwon J; Lim S; Helfman DM
    Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression.
    Asperger H; Stamm N; Gierke B; Pawlak M; Hofmann U; Zanger UM; Marton A; Katona RL; Buhala A; Vizler C; Cieslik JP; Ruckhäberle E; Niederacher D; Fehm T; Neubauer H; Ludescher M
    Breast Cancer Res; 2020 Jul; 22(1):75. PubMed ID: 32660617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.
    Ciardiello F; Tortora G
    Clin Cancer Res; 1998 Apr; 4(4):821-8. PubMed ID: 9563874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice.
    Kuang SQ; Liao L; Zhang H; Lee AV; O'Malley BW; Xu J
    Cancer Res; 2004 Mar; 64(5):1875-85. PubMed ID: 14996752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer.
    Kyriakopoulou K; Kefali E; Piperigkou Z; Bassiony H; Karamanos NK
    Cell Signal; 2018 Nov; 51():99-109. PubMed ID: 30071291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of Ras by SAF-1/MAZ through a feed-forward loop promotes angiogenesis in breast cancer.
    Ray A; Ray BK
    Cancer Med; 2015 Feb; 4(2):224-34. PubMed ID: 25449683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration.
    Cui X; Kim HJ; Kuiatse I; Kim H; Brown PH; Lee AV
    Cancer Res; 2006 May; 66(10):5304-13. PubMed ID: 16707456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.
    Eckert LB; Repasky GA; Ulkü AS; McFall A; Zhou H; Sartor CI; Der CJ
    Cancer Res; 2004 Jul; 64(13):4585-92. PubMed ID: 15231670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists.
    Johnston SR
    Int J Gynecol Cancer; 2006; 16 Suppl 2():543-8. PubMed ID: 17010069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.